Passage Bio

About

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Philadelphia,Pennsylvania,United States
51 - 100
http://www.passagebio.com

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $110M
Industries: Biotechnology,Health Care,Therapeutics,Wellness
Founded date: Jan 1, 2018
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:PASG
Legal Name: Passage Bio Inc.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$595.50M

Passage Bio has raised a total of $595.50M in funding over 2 rounds. Their latest funding was raised on Jan 21, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 21, 2021	Post-IPO Equity	$154M	—	—	—	Detail
Feb 27, 2020	IPO	$216M	—	—	—	Detail
Sep 4, 2019	Series B	$110M	11	Len Blavatnik	—	Detail
Feb 15, 2019	Series A	$115.50M	6	OrbiMed	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

11

Passage Bio is funded by 11 investors. Len Blavatnik and Boxer Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Len Blavatnik	Yes	Series B
Boxer Capital	—	Series B
Frazier Healthcare Partners	—	Series B
Highline Capital Management	—	Series B
Lilly Asia Ventures	—	Series B
Logos Capital	—	Series B
New Leaf Venture Partners	—	Series B
OrbiMed	—	Series B
Sphera Funds Management	—	Series B
Versant Ventures	—	Series B